The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

WBZ-TV's Dr. Mallika Marshall reports that drug maker Eli Lilly put its own weight loss drug Zepbound against the popular ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Only three drugs – Novo Nordisk’s Wegovy and Saxenda, and Eli Lilly’s Zepbound – are actually approved for that purpose. Now, if used correctly, these drugs can be a lifeline for patients.

A KFF survey from 2024 found people had superior weight loss results on Zepbound compared to Wegovy, ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...